Home > Insider Trading > Filing (0001399529-21-000016)

Filing Details

Accession Number:: 0001399529-21-000016
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-12 21:40:30
Reporting Period:: 2021-01-08

Accepted Time:: 2021-01-12 21:40:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1399529	Dicerna Pharmaceuticals Inc	DRNA	Pharmaceutical Preparations (2834)	205993609

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1598480	B James Weissman	C/O Dicerna Pharmaceuticals, Inc. 75 Hayden Avenue Lexington MA 02421	Chief Operating Officer & Evp	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-01-08	8,650	$0.00	40,510	No	4	M	Direct
Common Stock	Disposition	2021-01-08	2,842	$23.29	37,668	No	4	F	Direct
Common Stock	Disposition	2021-01-11	3,800	$23.99	33,868	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2021-01-08	8,650	$0.00	8,650	$0.00
Common Stock	Restricted Stock Units	Acquisiton	2021-01-12	15,100	$0.00	15,100	$0.00
Common Stock	Employee Stock Option (Right to Buy)	Acquisiton	2021-01-12	68,100	$0.00	68,100	$24.05

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
25,950		No	4	M	Direct
15,100		No	4	A	Direct
68,100	2031-01-11	No	4	A	Direct

Footnotes

Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.
Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
The Reporting Person sold an aggregate of 3,800 shares of Common Stock on January 11, 2021 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 0.52% of 732,596 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of January 11, 2021.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 8, 2020.
The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of January 8, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.
The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of December 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.
The option vests in 48 substantially equal monthly installments, with the first installment vesting on the last day of January 2021, and the remaining shares vesting on the last day of each of the 47 months thereafter; subject in each case to the Reporting Person's continued employment or service with the Issuer through each applicable vesting date.